4/A: Celularity Inc. Director Peter Diamandis Reports Acquisition of Stock Options and Restricted Stock Units

Director Peter Diamandis reports acquiring stock options and restricted stock units in Celularity Inc.

Summary

• On December 19, 2024, Peter Diamandis, a director of Celularity Inc., acquired 67,416 Class A Common Stock shares in the form of Restricted Stock Units (RSUs) at a price of $0.00.
• These RSUs were granted under the Celularity Inc. 2021 Equity Incentive Plan and represent the right to receive one share of the Issuer's Class A common stock per RSU.
• The RSUs will vest and become exercisable on the earlier of December 19, 2024 (one-year anniversary of the grant date) or the next annual stockholder meeting, contingent upon Diamandis' continuous service with Celularity Inc.
• Diamandis also acquired 84,746 stock options (right to buy) at an exercise price of $2.225 on the same date.
• These options were also granted under the 2021 Plan and will vest and become exercisable under the same conditions as the RSUs.
• Following these transactions, Diamandis beneficially owns 201,723 shares of Class A Common Stock and 416,459 stock options.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing. The acquisition of shares and options by a director is generally viewed as a neutral to slightly positive signal.

Positives

• The acquisition of RSUs and stock options by a director signals confidence in the company's future performance.

Future Outlook

The vesting of RSUs and stock options is contingent upon the director's continuous service with the company, incentivizing continued involvement.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, which can influence investor sentiment.

Comparison to Industry Standards

• Equity grants to directors are a common practice in publicly traded companies to align their interests with those of shareholders.
• The vesting schedules and terms of the 2021 Equity Incentive Plan are likely comparable to those of similar companies in the biotechnology sector.

Stakeholder Impact

• The reported transactions provide transparency to shareholders regarding the director's stake in the company.
• The vesting conditions of the RSUs and stock options incentivize the director to contribute to the company's long-term success.

Key Dates

Keywords

Celularity Inc, Peter Diamandis, RSUs, Stock Options, Beneficial Ownership, Director, Equity Incentive Plan, CELU